How fast is too fast when we are talking about the future of medicine? This is not a new question, but it is being asked at a time of unprecedented change and at the tipping point of a whole new generation of products starting to enter commercialization. Between Cell and Gene Therapy, mRNA vaccine technology, and the full width and breadth of other R&D efforts across the pharmaceutical and biopharmaceutical space, the drug development pipeline has grown from 11 to 21 percent since the global pandemic with no sign of slowing down. All this is happening during a time of…